Clinical trialNANot yet recruiting
Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations
- Outcome
- Ongoing
- Phase
- NA
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- June 2026
- Expected end
- June 2031
- Enrollment
- 40 participants
- Sites
- 1
- Primary outcomes
- Rate of sepsis within 72 hours of operations; Rate of transfusion related complication within the first 72 hours; Rate of all adverse events in the first post-operate week
- Sponsor
- Other
- Results posted
- No
- Last update
- 20 May 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery. Primary Objective: 1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 3. To summarize rates and timing of AEs in the first 7 post-operative days. Secondary Objectives: 1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room. 2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.